Telix Pharmaceuticals has entered an agreement to add Subtle Medical’s AI software for enhancing prostate-specific membrane antigen (PSMA) PET prostate cancer scans to its product portfolio.
SubtlePET is a U.S. Food and Drug Administration (FDA) cleared deep-learning algorithm designed to enhance the efficiency and effectiveness of imaging procedures, Telix said. The algorithm allows for faster PET scanning, up to 75% faster without compromising image quality, according to the company.
Telix’s leading PSMA-PET imaging kit, Illucix, is used to perform gallium-68 PSMA-11 imaging exams in men with prostate cancer. The partnership covers North America and the European Union (excluding France and French speaking Belgium), the company said.
